论文部分内容阅读
目的探讨异丙托溴铵联合舒利迭在治疗重度哮喘患者中的临床效果。方法 80例重度哮喘患者,采用随机数字法分为对照组和实验组,各40例。对照组采用舒利迭治疗,实验组在对照组基础上联合异丙托溴铵治疗。比较两组疗效。结果两组患者治疗前最大呼气量(FEV)、第一秒用力呼气容积(FEV1)以及呼气峰值流速(PEFR)比较,差异无统计学意义(P>0.05);实验组治疗后FEV、FEV1以及PEFR显著高于对照组,差异有统计学意义(P<0.05)。结论重度哮喘患者在舒利迭基础上联合异丙托溴铵治疗效果理想,能够改善患者肺功能,值得临床推广应用。
Objective To investigate the clinical efficacy of ipratropium bromide combined with seretide in the treatment of patients with severe asthma. Methods Eighty patients with severe asthma were randomly divided into control group and experimental group with 40 cases in each group. The control group was treated with seretide, and the experimental group was treated with ipratropium bromide on the basis of the control group. Compare the two groups curative effect. Results There was no significant difference in FEV, FEV1 and PEFR between the two groups before and after treatment (P> 0.05). After treatment, FEV , FEV1 and PEFR were significantly higher than the control group, the difference was statistically significant (P <0.05). Conclusion Severe asthma patients combined with ipratropium bromide on the basis of seretide treatment effect is ideal, can improve lung function in patients, it is worthy of clinical promotion and application.